Archford Capital Strategies LLC Sells 2,070 Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Archford Capital Strategies LLC lowered its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 5.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 33,462 shares of the company’s stock after selling 2,070 shares during the period. Archford Capital Strategies LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $325,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. McGuire Investment Group LLC grew its stake in Global X Genomics & Biotechnology ETF by 3.5% in the fourth quarter. McGuire Investment Group LLC now owns 58,109 shares of the company’s stock valued at $564,000 after acquiring an additional 1,940 shares during the period. Oxinas Partners Wealth Management LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF in the 4th quarter valued at approximately $103,000. Flow Traders U.S. LLC bought a new stake in Global X Genomics & Biotechnology ETF during the 3rd quarter worth approximately $936,000. Rockefeller Capital Management L.P. acquired a new stake in Global X Genomics & Biotechnology ETF during the 3rd quarter worth approximately $205,000. Finally, Centaurus Financial Inc. lifted its stake in Global X Genomics & Biotechnology ETF by 7.0% in the third quarter. Centaurus Financial Inc. now owns 14,996 shares of the company’s stock valued at $169,000 after buying an additional 985 shares in the last quarter. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Down 1.1 %

Global X Genomics & Biotechnology ETF stock opened at $10.18 on Monday. Global X Genomics & Biotechnology ETF has a twelve month low of $9.50 and a twelve month high of $12.53. The company has a 50 day moving average of $10.14 and a 200-day moving average of $10.74. The stock has a market capitalization of $70.95 million, a PE ratio of -4.35 and a beta of 1.03.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.